Fractyl Health (GUTS) Total Non-Current Liabilities (2023 - 2026)
Fractyl Health's (GUTS) quarterly Total Non-Current Liabilities came in at $77.4 million in Q1 2026, up 2.24% YoY from $75.7 million in Q1 2025, and down 30.41% on a QoQ basis from $111.3 million in Q4 2025.
Fractyl Health (GUTS) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Total Non-Current Liabilities data on file, last reported at $77.4 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 2.24% year-over-year to $77.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.4 million (up 2.24% YoY) and the FY2025 annual result came in at $111.3 million, up 41.48% from the prior year.
- Total Non-Current Liabilities retreated to $77.4 million in Q1 2026, from $111.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $116.7 million in Q3 2025 to a low of -$2.6 million in Q3 2023.
- A 4-year average of $76.6 million and a median of $78.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 3005.0% — and 2025, when it slipped 4.13%.
- Tracing GUTS's Total Non-Current Liabilities over 4 years: stood at -$2.6 million in 2023, then soared by 3125.19% to $78.7 million in 2024, then surged by 41.48% to $111.3 million in 2025, then slumped by 30.41% to $77.4 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $77.4 million (Q1 2026), $111.3 million (Q4 2025), and $116.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Fractyl Health | 109.12 Mn | 109.12 Mn | - | 83.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.13 Mn |
| Mar 31, 2026 | 77.44 Mn |
| Dec 31, 2025 | 111.28 Mn |
| Sep 30, 2025 | 116.70 Mn |
| Jun 30, 2025 | 79.38 Mn |
| Mar 31, 2025 | 75.75 Mn |
| Dec 31, 2024 | 78.66 Mn |
| Sep 30, 2024 | 75.53 Mn |
| Jun 30, 2024 | 74.72 Mn |
| Mar 31, 2024 | 79.01 Mn |
| Sep 30, 2023 | -2.60 Mn |